Duloxetina

證據等級: L5

預測適應症: 0 個

DULOXETINA: Evaluation Suspended – Incomplete Evidence Pack

One-Sentence Summary

Duloxetina (Duloxetine) is an internationally recognized serotonin-norepinephrine reuptake inhibitor (SNRI), approved in multiple countries for major depressive disorder, generalized anxiety disorder, and neuropathic pain. However, this Evidence Pack contains no TxGNN-predicted new indications, no Italy regulatory records, and no safety data, making a standard drug repurposing evaluation impossible at this stage. A corrected re-query with the proper DrugBank identifier is required before any evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not recorded in Italy regulatory database
Predicted New Indication	None (TxGNN predictions absent)
TxGNN Prediction Score	N/A
Evidence Level	Not assessable
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Are No Predictions Available?

Duloxetina returned zero results from the Italy (AIFA) regulatory database, and the Evidence Pack carries no DrugBank ID. Without a valid DrugBank node, the TxGNN knowledge graph pipeline cannot map the drug to any disease node and therefore produces no predicted indications.

This is almost certainly a data linkage problem, not a genuine absence of repurposing potential. Duloxetine is a well-characterized compound with an established mechanism (dual inhibition of the serotonin transporter SERT and the norepinephrine transporter NET) and an active research portfolio covering cancer-related neuropathic pain, stress urinary incontinence, fibromyalgia, and chemotherapy-induced peripheral neuropathy, among others.

The most likely root causes are: (1) the INN spelling "DULOXETINA" not matching the AIFA database entry (which may index under "duloxetina" with lower-case, or by brand names Cymbalta / Xeristar), and (2) the absence of a DrugBank ID preventing TxGNN from running. Correcting these two points should unlock both the MOA data and the full prediction set.

Italy Market Information

No authorizations were found in the Italy regulatory database for the query term "DULOXETINA".

Note: Duloxetine is commercially available in Italy under the brand names Cymbalta and Xeristar. The zero-result query likely reflects a spelling mismatch or search-scope limitation in the automated pipeline rather than actual market absence. A manual AIFA search using the brand name or the lowercase INN "duloxetina" is recommended.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN-predicted indications, no AIFA regulatory records, and no safety warnings — none of the minimum data required for a Level-1 to Level-5 evidence assessment is present. Proceeding to evaluation would produce a structurally empty report with no actionable content.

To proceed, the following is needed:

Resolve DrugBank ID: Duloxetine's likely identifier is DB00476; confirm and re-inject into the pipeline.
Re-query AIFA: Use lowercase "duloxetina" and/or brand names "Cymbalta" / "Xeristar" to retrieve existing Italy market authorizations and approved indications.
Re-run TxGNN: With a valid DrugBank ID, re-execute the knowledge-graph prediction step to generate ranked predicted indications.
Retrieve package insert: Download the AIFA/TFDA package insert PDF to populate key warnings, contraindications, and DDI data.
Resubmit a complete Evidence Pack: Once the above gaps are resolved, regenerate the Evidence Pack and return for a full evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.